Investigation launched into Qiagen for possible securities law violations after revised sales guidance.

Levi & Korsinsky has started an investigation into Qiagen N.V. following the company's significant downgrade of its sales forecast. CEO Thierry Bernard had previously projected 6-7% growth in QuantiFERON sales for 2026, but CFO Roland Sackers later revised this, stating sales would remain flat from Q2 2025 levels and growth would normalize only in 2027. The investigation focuses on whether Qiagen violated federal securities laws by providing misleading guidance. Investors who suffered losses may seek recovery through legal channels offered by Levi & Korsinsky, a firm experienced in securities litigation.